MedTrace Logo

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer

NCT06018883 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of low-dose vitamin C on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.

Conditions

  • Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG

Ascorbate

Vitamin C 900 mg/day, three times a day, orally.

DRUG

Nab paclitaxel

Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks

DRUG

Gemcitabine

Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Guopei Luo, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-20
Primary Completion
2025-08-15
Completion
2026-08-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06018883 on ClinicalTrials.gov